Macimorelin
Macrilen, Macimorelin Aeterna Zentaris (macimorelin) is a small molecule pharmaceutical. Macimorelin was first approved as Macrilen on 2017-12-20. It has been approved in Europe to treat endocrine diagnostic techniques. The pharmaceutical is active against growth hormone secretagogue receptor type 1. Macrilen's patent is valid until 2027-10-12 (FDA).
| Trade Name | Macimorelin Aeterna Zentaris |
|---|---|
| Common Name | Macimorelin |
| Indication | endocrine diagnostic techniques |
| Drug Class | Prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides |
